I

Infinity Dermatology NYC | Forest Hills Dermatology Group

Research site
(Unclaimed)
Location
80-02 Kew GaRoadens Road, Suite 107, Kew Gardens, New York, United States of America
Site insights

Top conditions

Eczema (16 trials)

Atopic Dermatitis (15 trials)

Dermatitis (15 trials)

Psoriasis (7 trials)

Eczematous Skin Diseases (2 trials)

Top treatments

PF-04965842
Rocatinlimab
Risankizumab
BMS-986165
Upadacitinib
Ruxolitinib
AMG 451
Dupilumab
Difamilast
MOB015B

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

13 of 25
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

This is a Phase 3, open-label study to evaluate the long-term safety of difamilast ointment 1% in subjects ≥2 years of age with mild to moderate AD....

Active, not recruiting
Atopic Dermatitis
Drug: Difamilast

The co-primary objectives of the study are to:Evaluate the efficacy of rocatinlimab compared with placebo at Week 24, assessed using Validated Invest...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The primary objectives of this study are to:estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus re...

Active, not recruiting
Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. There...

Active, not recruiting
Psoriasis
Drug: Ustekinumab
Drug: Risankizumab

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

This is a Phase 3 multicenter, double-blind study to evaluate the safety and efficacy of vehicle-controlled topical MOB015B in the treatment of Dista...

Active, not recruiting
Onychomycosis
Drug: Vehicle (Placebo Comparator)
Drug: MOB015B

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Placebo for Upadacitinib

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe...

Enrolling
Atopic Dermatitis
Biological: OpSCF
Biological: Placebo

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will asse...

Enrolling
Scalp Psoriasis
Genital Psoriasis
Drug: Risankizumab
Drug: Placebo for Risankizumab
Locations recently updated

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 100 mg
Drug: Placebo

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CH...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

Trial sponsors

AbbVie logo

AbbVie (7 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems